Business context and reporting period
Entity note: The supplied filing is CryoLife, Inc.’s Form 10-K, not an Artivion, Inc. filing. It covers the fiscal year ended December 31, 2014; fourth-quarter figures are also disclosed. CryoLife manufactures and distributes surgical sealants and hemostats, cardiac laser products and vascular-access devices, and provides preservation services for human cardiac and vascular tissues.
Revenue is reported in two principal business areas: Medical Devices and Preservation Services. BioGlue was the largest product, contributing 43% of 2014 revenue. The company appointed James P. Mackin CEO in September 2014.
Financial performance and position
| Metric | FY 2014 | FY 2013 | Change / context |
|---|---|---|---|
| Revenue | $144.6 million | $140.8 million | Up 3% |
| Gross profit / margin | $91.3 million / 63% | $90.4 million / 64% | Profit up 1%; margin down 1 percentage point |
| Operating income | $8.8 million | $13.8 million | Down 36% |
| Net income | $7.3 million | $16.2 million | Down 55%; prior year included a $12.7 million Medafor investment gain |
| Diluted EPS | $0.25 | $0.57 | Prior-year comparison also reflects the Medafor gain |
| Operating cash flow | $8.1 million | $16.8 million | Down; working-capital needs increased |
Fourth-quarter revenue was $37.2 million, up 5% year over year; net income was $1.8 million versus $9.0 million, and diluted EPS was $0.06 versus $0.31. The 2013 quarter included the Medafor gain.
Medical Devices revenue increased 7% to $81.9 million, led by BioGlue/BioFoam ($62.1 million), PerClot ($4.3 million) and HeRO Graft ($7.1 million). Preservation Services revenue declined 3% to $62.8 million, including cardiac tissue revenue of $29.4 million and vascular tissue revenue of $33.3 million. Lower tissue shipments and throughput pressured preservation margins; product revenue mix partly offset the effect.
At year-end, cash and cash equivalents were $33.4 million; working capital was $85.4 million and the current ratio was 5:1. The company had no borrowings outstanding on its $20 million revolving facility, with all $20 million available, and reported total liabilities of $27.5 million. A further $5.0 million of cash was restricted under the credit agreement. Capital expenditures were $4.3 million. Financing cash use included $5.6 million of share repurchases and $3.3 million of dividends paid.
Material changes, outlook and notable items
- Operating trend: Product growth more than offset lower preservation-services revenue. Gross margin fell to 63%, while operating expenses rose: general, administrative and marketing expense increased 8% to $73.8 million.
- Management outlook: No consolidated revenue or earnings guidance is provided. Management expected 2015 growth in PerClot and HeRO Graft, a slight increase in cardiac laser revenue, and slight full-year increases in cardiac and vascular preservation revenue. It cautioned that preservation revenue could decline in the first quarter and improve later. Management expected higher 2015 general, administrative and marketing costs and a material increase in R&D spending, primarily for the PerClot clinical trial.
- Regulatory exposure: FDA inspections resulted in a 2013 Warning Letter and 2014 Form 483 observations covering validation, environmental monitoring, product controls, corrective actions and training. Tissue-processing changes and a voluntary distribution restriction reduced tissue availability and increased costs; management said the work would continue into 2015. FDA reinspection was expected in early 2015.
- Product approval risk: The PerClot surgical pivotal trial was expected to begin enrollment in the first half of 2015, with PMA anticipated in 2017. The CryoValve SGPV could be reclassified as a Class III device, potentially requiring a PMA and threatening continued distribution if approval is delayed, denied or uneconomic.
- Litigation: CryoLife and Bard/Medafor were litigating whether U.S. PerClot sales infringe Bard’s patent. Bard sought a preliminary injunction; a hearing took place January 23, 2015, and the filing said a ruling was expected imminently. Litigation costs were expected to be significant in 2015.
- Unusual items and contingencies: CryoLife recorded a $2.0 million write-down of its ValveXchange note receivable, which it considered fully impaired; bankruptcy was possible. The company received a $530,000 Medafor escrow release in 2014 and could receive up to a further $7.9 million, subject to escrow and sales milestones. ProCol distribution began in 2014; PhotoFix distribution began in January 2015.
- Other risks: BioGlue concentration, single-source suppliers, dependence on donated tissue, foreign exchange, reimbursement and hospital-budget pressures, and credit-agreement covenants may affect results and liquidity. The company reported effective internal controls and unqualified audit opinions on its financial statements and internal control over financial reporting.
Key facts for investors to verify
- Confirm the issuer identity: this source is CryoLife, Inc., despite the request metadata naming Artivion, Inc.
- Track the FDA’s response to the 2014 Form 483 and the outcome of the anticipated reinspection, including any impact on tissue availability and costs.
- Check the Bard/Medafor injunction and patent litigation outcomes and their effects on U.S. PerClot commercialization and expenses.
- Monitor PerClot trial enrollment, spending and regulatory milestones, and the FDA’s eventual classification and PMA requirements for CryoValve SGPV.
- Assess whether product growth offsets preservation-services pressure and higher operating expenses, and whether 2015 cash generation supports planned R&D, litigation, dividends and other commitments.
- Verify the timing and amount, if any, of additional Medafor escrow or earnout proceeds and any recovery from the impaired ValveXchange loan.